Buscar
-
Effectiveness and Safety of Standard and Reduced Doses of Dabigatran Compared to Rivaroxaban in Nonvalvular Atrial Fibrillation: Long-Term Results from a Cohort Study in the French Nationwide Claims Database
(Journal of the American College of Cardiology. vol. 75, n° 11, pp. 357, 2020)Article de revue -
Effectiveness and safety of standard and reduced doses of dabigatran versus rivaroxaban in non-valvular atrial fibrillation: A cohort study in the snds french nationwide claims database
(Value Health. vol. 21, pp. S7-S7, 2018-10)Article de revue -
Benefit-risk profile of dabigatran compared with vitamin-K antagonists in elderly patients with non-valvular atrial fibrillation: results from a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 822-822, 2018-08)Article de revue -
Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study
(Pharmacological Research. vol. 141, pp. 201-207, 2019)Article de revue -
Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study
(Drug safety. vol. 42, n° 8, pp. 993-1003, 2019-08)Article de revue -
SNDS, the french nationwide claims database: A powerful tool for pharmacoeconomy and pharmacoepidemiology
(Value Health. vol. 21, pp. S371-S371, 2018-10)Article de revue -
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation
(Stroke. vol. 50, n° 9, pp. 2469-2476, 2019)Article de revueLibre acceso -
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
(EP-Europace. vol. 22, n° 2, pp. 205-215, 2020)Article de revue -
Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI
(Thérapie. vol. 74, n° 4, pp. 459-468, 2019-09)Article de revue -
Benefit-risk of rivaroxaban 20 or 15mg compared to vitamin-K antagonists in patients with non-valvular atrial fibrillation: a cohort study in the French nationwide claims database
(European Heart Journal. vol. 39, pp. 1014-1014, 2018-08)Article de revue